Heron Therapeutics (HRTX) has released an update.
Heron Therapeutics, Inc. announced on January 23, 2024, that the FDA approved the expanded use of ZYNRELEF® (bupivacaine and meloxicam) for soft tissue and orthopedic surgical procedures, specifically excluding those involving direct exposure to articular cartilage.
For further insights into HRTX stock, check out TipRanks’ Stock Analysis page.
